Infliximab

also known as Remicade · IFX · CT-P13 · TA-650 · Inflectra · Remsima · Infliximab-dyyb · CMAB008 · +21 more

Monoclonal antibody targets TNF via inhibition

Developed for: Crohn disease · rheumatoid arthritis · ulcerative colitis · psoriasis · ankylosing spondylitis · psoriatic arthritis · inflammatory bowel disease · spondyloarthropathy
+89 more
· COVID-19 · Kawasaki disease · Behcet disease · depressive disorder · uveitis · sarcoidosis · Takayasu arteritis · acute graft versus host disease · arthritic joint disease · chronic hepatitis C virus infection · chronic obstructive pulmonary disease · colitis · corneal disorder · graft versus host disease · hidradenitis suppurativa · melanoma · metastatic melanoma · Stevens-Johnson syndrome · vasculitis · acute kidney injury · acute tubulointerstitial nephritis · asthma · atopic eczema · bipolar depression · brain aneurysm · cardiac arrest · chemical colitis · chronic beryllium disease · cytokine release syndrome · dermatomyositis · diabetic macular edema · diabetic retinopathy · dry eye syndrome · eating disorder · endometriosis · esophagitis · glaucoma · granulomatosis with polyangiitis · hypertensive disorder · hypoproteinemia, hypercatabolic · idiopathic scleritis · juvenile idiopathic arthritis · lumbar stenosis, familial · lupus nephritis · macular degeneration · macular retinal edema · major depressive disorder · microscopic polyangiitis · mucous membrane pemphigoid · myelodysplastic syndrome · myositis disease · osteoarthritis, knee · pemphigus · perianal Crohn disease · polyarticular juvenile idiopathic arthritis · polyarticular juvenile rheumatoid arthritis · polymyalgia rheumatica · post-cardiac arrest syndrome · pustular psoriasis · pyoderma gangrenosum · reactive arthritis · relapsing polychondritis · schizophrenia · scleritis · Sjogren syndrome · small bowel Crohn disease · spondylitis · systemic lupus erythematosus · temporal arteritis · toxic epidermal necrolysis · transplant rejection · tropical spastic paraparesis · type 1 diabetes mellitus · acute pancreatitis · age-related macular degeneration · anal fistula · choroidal neovascularization · Cogan syndrome · COVID-19–associated multisystem inflammatory syndrome in children · Cryoglobulinemic vasculitis · cutaneous polyarteritis nodosa · eosinophilic granulomatosis with polyangiitis · immunoglobulin A vasculitis · metabolic syndrome X · obesity disorder · primary central nervous system vasculitis · proliferative vitreoretinopathy · rhegmatogenous retinal detachment · type 2 diabetes mellitus
Investigated by: Centocor, Inc. · Merck Sharp & Dohme LLC · Celltrion · Tanabe Pharma Corporation · Emory University · Schering-Plough
+259 more
· Assistance Publique - Hôpitaux de Paris · Centocor Ortho Biotech Services, L.L.C. · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Massachusetts General Hospital · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · National Institute of Mental Health (NIMH) · Academic Medical Center - University of Amsterdam · Children's Hospital Medical Center, Cincinnati · Erasmus Medical Center · Icahn School of Medicine at Mount Sinai · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · University of California, San Francisco · World Health Organization · Xian-Janssen Pharmaceutical Ltd. · Asan Medical Center · Charite University, Berlin, Germany · Children's Hospital of Fudan University · Diakonhjemmet Hospital · Fonds de recherche en ophtalmologie de l'Université de Montréal · Helsinki University Central Hospital · Hvidovre University Hospital · Imperial College London · Integrated Therapeutics Group · Janssen Research & Development, LLC · Janssen Scientific Affairs, LLC · Massachusetts Eye and Ear Infirmary · Medical Research Council · Medical University of Graz · Medical University of Vienna · NYU Langone Health · National Cancer Institute (NCI) · Nationwide Children's Hospital · Oregon Health and Science University · Pfizer · Seoul National University Hospital · Services Institute of Medical Sciences, Pakistan · Shanghai 10th People's Hospital · Shanghai Children's Medical Center · Sixth Affiliated Hospital, Sun Yat-sen University · Taizhou Mabtech Pharmaceutical Co.,Ltd · University Health Network, Toronto · University Medical Center Groningen · University of California, San Diego · University of Erlangen-Nürnberg Medical School · University of Leeds · University of Montreal Hospital Centre (CHUM) · University of Roma La Sapienza · AESCA Pharma GmbH · Aalborg University Hospital · AbbVie · All India Institute of Medical Sciences · Alliance for Clinical Trials in Oncology · American Cancer Society, Inc. · Apotex Inc. · Arch Biopartners Inc. · Asian Institute of Gastroenterology, India · Association de Recherche Clinique en Rhumatologie · Autoimmunity Centers of Excellence · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Beth Israel Deaconess Medical Center · Biocad · Bnai Zion Medical Center · Bristol-Myers Squibb · Bühlmann Laboratories AG · CMC Ambroise Paré · Cairo University · Carmel Medical Center · Celltrion HealthCare France · Center for Integrated Rehabilitation and Organ Failure Horn · Central South University · Changhai Hospital · Chiba University · City of Helsinki · all 265 on the full record

Regulatory milestones approvals, filings & regulatory actions · 19 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansion	US (FDA)	RENFLEXIS	—	2019-06-26	fda.gov ↗
Label expansion	US (FDA)	INFLECTRA	—	2019-06-18	fda.gov ↗
Label expansions (15)	US (FDA)	REMICADE	—	1999-11-10 – 2011-09-23	fda.gov ↗
Approved	EU (EMA)	Remicade	—	1999-08-13	europa.eu ↗
Approved	US (FDA)	REMICADE	—	1998-08-24	fda.gov ↗

Trials 239 · started per year

today

US approved 1998

EU approved 1999

1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT05663268	Oct 2022 → Mar 2023	hidradenitis suppurativa	Services Institute of Medical Sciences, Pakistan	Completed	No outcome recorded
Phase 111 trials
Phase 1	NCT04779892	Feb → Jun 2020	rheumatoid arthritis	Taizhou Mabtech Pharmaceutical Co.,Ltd	Completed	No outcome recorded
Phase 1	NCT03446976	Feb → Jul 2018	—	Celltrion	Completed	No outcome recorded
Phase 1	NCT03293784	Oct 2017 → Dec 2019	melanoma	Institut Claudius Regaud	Completed	No outcome recorded
Phase 1	NCT02987686	Sep 2017 → Nov 2025	corneal disorder	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 1	NCT02359903	Feb → Nov 2015	ankylosing spondylitis	Biocad	Completed	No outcome recorded
Phase 1	NCT01971814	Nov 2013 → Jan 2015	ulcerative colitis	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT01922336	Jul → Oct 2013	—	Samsung Bioepis Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT00695682	Jun → Dec 2008	diabetic retinopathy, macular degeneration	Retina Research Foundation	Unknown	No outcome recorded
Phase 1	NCT00271570	Apr 2004 → Oct 2006	Kawasaki disease	University of California, San Diego	Completed	No outcome recorded
Phase 1	NCT00075075	Dec 2003 → Sep 2007	scleritis	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 1	NCT00228839	? → Oct 2006	acute graft versus host disease	Emory University	Completed	No outcome recorded

Phase 1/210 trials
Phase 1/2	NCT02638701	Oct 2024 → Jun 2028 expected	brain aneurysm, stroke disorder, vasculitis	University of California, San Francisco	Recruiting	No outcome recorded
Phase 1/2	NCT06591273	Nov 2023 → Nov 2024 overdue	psoriasis	Services Institute of Medical Sciences, Pakistan	Active not recruiting	No outcome recorded
Phase 1/2	NCT05180994	May 2022 → Mar 2027 expected	glaucoma	University of Montreal Hospital Centre (CHUM)	Recruiting	No outcome recorded
Phase 1/2	NCT02126020	Nov 2014 → Apr 2017	Stevens-Johnson syndrome, mucous membrane pemphigoid	James Chodosh, MD, MPH	Withdrawn	No outcome recorded
Phase 1/2	NCT02620618	Jan 2013 → Dec 2014	Behcet disease, uveitis	Cairo University	Completed	No outcome recorded
Phase 1/2	NCT01256489	Dec 2010 → Jan 2015	Stevens-Johnson syndrome, corneal disorder	Massachusetts Eye and Ear Infirmary	Withdrawn	No outcome recorded
Phase 1/2	NCT00959725	Aug 2009 → Aug 2011	diabetic macular edema	Icahn School of Medicine at Mount Sinai	Unknown	No outcome recorded
Phase 1/2	NCT00958906	Aug → Oct 2009	macular retinal edema, uveitis	Icahn School of Medicine at Mount Sinai	Withdrawn	No outcome recorded
Phase 1/2	NCT00325078	May 2006 → Jun 2012	Crohn disease, chronic granulomatous disease	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 1/2	NCT00111917	Feb 2005 → Jan 2009	chronic beryllium disease	Maier, Lisa, M.D.	Terminated	No outcome recorded
Phase 245 trials
Phase 2	NCT07671222	Dec 2026 → Mar 2028 expected	Sjogren syndrome, dry eye syndrome	Instituto de Oftalmología Fundación Conde de Valenciana	Not yet recruiting	No outcome recorded
Phase 2	NCT07657312	Aug 2026 → Dec 2027 expected	cytokine release syndrome, plasma cell myeloma	Naresh Bumma	Recruiting	No outcome recorded
Phase 2	NCT07297069	Jan 2026 → May 2027 expected	ulcerative colitis	Asian Institute of Gastroenterology, India	Not yet recruiting	No outcome recorded
Phase 2	NCT07138898	Dec 2025 → Jan 2028 expected	rheumatic disorder	NYU Langone Health	Recruiting	No outcome recorded
Phase 2	NCT06941376	Aug 2025 → Jul 2027 expected	relapsing polychondritis	University of Pennsylvania	Recruiting	No outcome recorded
Phase 2	NCT06453317	Feb 2025 → Apr 2028 expected	ulcerative colitis	Medical University of Lodz	Recruiting	No outcome recorded
Phase 2	NCT06136546	Jan 2025 → Aug 2028 expected	major depressive disorder	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 2	NCT05034536	Feb 2022 → Jun 2026 overdue	metastatic melanoma	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 2	NCT04922827	Jun 2021 → Mar 2023	COVID-19	Jena University Hospital	Completed	No outcome recorded
Phase 2	NCT04438382	Jan 2021 → Dec 2023	cancer, hematopoietic and lymphoid cell neoplasm	ECOG-ACRIN Cancer Research Group	Terminated	No outcome recorded
Phase 2	NCT04564001	Sep 2020 → Feb 2021	Takayasu arteritis	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
Phase 2	NCT04305145	Aug 2020 → Jun 2030 expected	chemical colitis, metastatic melanoma, poisoning, skin cancer	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 2	NCT04425538	Jun 2020 → Jan 2021	COVID-19	Tufts Medical Center	Completed	No outcome recorded
Phase 2	NCT04114188	Dec 2016 → Dec 2020	transplant rejection	Prof. Dr. Petra Reinke	Completed	No outcome recorded
Phase 2	NCT02763761	Aug 2016 → Mar 2017	lung cancer, melanoma, renal cell carcinoma	Bristol-Myers Squibb	Withdrawn	No outcome recorded
Phase 2	NCT02495077	Nov 2015 → Jul 2021	—	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT02363738	Sep 2015 → Apr 2017	bipolar depression	University Health Network, Toronto	Completed	No outcome recorded
Phase 2	NCT02457585	Mar 2015 → Aug 2017	Takayasu arteritis	Seoul National University Hospital	Unknown	No outcome recorded
Phase 2	NCT01485055	Dec 2011 → Dec 2015	acute graft versus host disease	Nationwide Children's Hospital	Terminated	No outcome recorded
Phase 2	NCT01355614	Jun 2011 → Mar 2013	Crohn disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01313520	Mar 2011 → Mar 2012	rheumatoid arthritis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT01216631	Sep 2010 → Aug 2011	spondyloarthropathy	University of Leeds	Terminated	No outcome recorded
Phase 2	NCT00823641	Oct 2008 → Mar 2011	tropical spastic paraparesis	Imperial College London	Terminated	No outcome recorded
Phase 2	NCT00514982	Aug 2007 → Mar 2011	Hermansky-Pudlak syndrome, colitis	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 2	NCT00523354	Aug → Sep 2007	esophagitis	Swiss EE Study Group	Completed	No outcome recorded
Phase 2	NCT00512278	Jul 2007 → May 2012	chronic hepatitis C virus infection	Nizar Zein	Completed	No outcome recorded
Phase 2	NCT00372723	Jul 2006 → Jun 2011	toxic epidermal necrolysis	Loyola University	Withdrawn	No outcome recorded
Phase 2	NCT00687362	May 2006 → Nov 2008	psoriasis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00283712	Mar 2006 → Dec 2010	pemphigus	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00795574	Jun 2005 → Aug 2008	hidradenitis suppurativa	Florida Academic Dermatology Centers	Completed	No outcome recorded
Phase 2	NCT00112749	Feb 2005 → Jan 2007	breast cancer	Jonsson Comprehensive Cancer Center	Terminated	No outcome recorded
Phase 2	NCT00201799	Feb 2004 → Aug 2006	graft versus host disease	Ohio State University Comprehensive Cancer Center	Completed	No outcome recorded
Phase 2	NCT00604864	Feb 2004 → Feb 2005	endometriosis	KU Leuven	Completed	No outcome recorded
Phase 2	NCT00076726	Nov 2003 → Jul 2005	temporal arteritis	Centocor, Inc.	Terminated	No outcome recorded
Phase 2	NCT00244192	Oct 2003 → Dec 2005	chronic obstructive pulmonary disease	Center for Integrated Rehabilitation and Organ Failure Horn	Completed	No outcome recorded
Phase 2	NCT00074074	Oct 2003 → Dec 2006	myelodysplastic syndrome	European Organisation for Research and Treatment of Cancer - EORTC	Completed	No outcome recorded
Phase 2	NCT00060502	Apr 2003 → Feb 2006	hypoproteinemia, hypercatabolic, pancreatic neoplasm	Centocor, Inc.	Completed	No outcome recorded
Phase 2	NCT00753103	Jan 2003 → Jul 2006	granulomatosis with polyangiitis, microscopic polyangiitis	University Hospital Birmingham NHS Foundation Trust	Completed	No outcome recorded
Phase 2	NCT00244179	Jan 2003 → ?	reactive arthritis	Charite University, Berlin, Germany	Unknown	No outcome recorded
Phase 2	NCT00033891	Apr 2002 → Jul 2007	dermatomyositis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	No outcome recorded
Phase 2	NCT00029042	Jan 2002 → Oct 2005	polyarticular juvenile rheumatoid arthritis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Terminated	No outcome recorded
Phase 2	NCT00278083	Oct 2001 → Apr 2004	asthma	Imperial College London	Completed	No outcome recorded
Phase 2	NCT00006292	Sep 2000 → Sep 2005	rheumatoid arthritis	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	No outcome recorded
Phase 2	NCT00175266	—	type 1 diabetes mellitus	University of Alberta	Completed	No outcome recorded
Phase 2	NCT00230529	? → Jan 2003	psoriasis	Centocor, Inc.	Completed	No outcome recorded

Phase 2/37 trials
Phase 2/3	NCT05660746	Jul 2023 → Mar 2027 expected	Crohn disease	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 2/3	NCT04974099	Oct 2021 → Aug 2024	Crohn disease	Children's Hospital Medical Center, Cincinnati	Terminated	No outcome recorded
Phase 2/3	NCT00521963	Mar 2010 → Mar 2011	arthritic joint disease	HaEmek Medical Center, Israel	Withdrawn	No outcome recorded
Phase 2/3	NCT00368264	Sep 2006 → Jun 2009	lupus nephritis, systemic lupus erythematosus	Medical University of Vienna	Terminated	No outcome recorded
Phase 2/3	NCT00591201	Jun 2002 → Jun 2007	spondyloarthropathy	Hospital General de Mexico	Completed	No outcome recorded
Phase 2/3	NCT00269854	Jun 1995 → Oct 1996	Crohn disease	Centocor, Inc.	Completed	No outcome recorded
Phase 2/3	NCT00443222	—	myositis disease	Karolinska Institutet	Completed	No outcome recorded
Phase 378 trials
Phase 3	NCT06738719	Jan → Jun 2025	—	Celltrion	Completed	No outcome recorded
Phase 3	NCT06614387	Oct 2024 → Apr 2028 expected	ulcerative colitis	JAROSLAW KIERKUS	Not yet recruiting	No outcome recorded
Phase 3	NCT06274294	Jul 2024 → Jan 2025	inflammatory bowel disease	CMC Ambroise Paré	Unknown	No outcome recorded
Phase 3	NCT05947669	Aug 2023 → Sep 2026 expected	colitis	Odense University Hospital	Recruiting	No outcome recorded
Phase 3	NCT05689879	Mar 2023 → Jan 2027 expected	sarcoidosis	Assistance Publique - Hôpitaux de Paris	Active not recruiting	No outcome recorded
Phase 3	NCT06059989	Nov 2021 → Jun 2025 overdue	Crohn disease, inflammatory disease	Academic Medical Center - University of Amsterdam	Recruiting	No outcome recorded
Phase 3	NCT04610476	Oct 2020 → Oct 2024	psoriatic arthritis, substance withdrawal syndrome	University of Erlangen-Nürnberg Medical School	Unknown	No outcome recorded
Phase 3	NCT04535518	Oct 2020 → Sep 2022	Kawasaki disease	Children's Hospital of Fudan University	Withdrawn	No outcome recorded
Phase 3	NCT04205643	Sep 2020 → Jul 2022	ulcerative colitis	Celltrion	Completed	No outcome recorded
Phase 3	NCT03088293	Jun 2020 → Oct 2023	idiopathic scleritis	Hospices Civils de Lyon	Withdrawn	No outcome recorded
Phase 3	NCT04330690	Mar 2020 → Mar 2024	COVID-19	Sunnybrook Health Sciences Centre	Unknown	No outcome recorded
Phase 3	NCT03945019	Oct 2019 → Aug 2022	Crohn disease	Celltrion	Completed	No outcome recorded
Phase 3	NCT03704610	Mar 2019 → Jun 2021	sarcoidosis	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT03704363	Dec 2018 → Jul 2023	—	Oslo University Hospital	Completed	No outcome recorded
Phase 3	NCT03596645	Oct 2018 → Nov 2023 overdue	ulcerative colitis	Janssen Research & Development, LLC	Active not recruiting	No outcome recorded
Phase 3	NCT03371095	May 2018 → Dec 2021	Behcet disease, vasculitis	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT02990806	Jan 2017 → May 2019	rheumatoid arthritis	Nichi-Iko Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT02771457	Jul 2016 → Jul 2019	inflammatory bowel disease	NYU Langone Health	Withdrawn	No outcome recorded
Phase 3	NCT02505568	Jul 2015 → Jul 2018	Behcet disease	Janssen Korea, Ltd., Korea	Completed	No outcome recorded
Phase 3	NCT02096861	Sep 2014 → Jan 2016	Crohn disease	Celltrion	Completed	No outcome recorded
Phase 3	NCT02298062	Jan 2013 → Jul 2015	Kawasaki disease	Fudan University	Completed	No outcome recorded
Phase 3	NCT01680159	Jul 2012 → Mar 2015	psoriatic arthritis, pustular psoriasis	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 3	NCT01596335	May 2012 → Oct 2014	Kawasaki disease	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 3	NCT01551290	Apr 2012 → Mar 2014	ulcerative colitis	Xian-Janssen Pharmaceutical Ltd.	Completed	No outcome recorded
Phase 3	NCT01580670	Mar 2012 → Mar 2015	Crohn disease	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 3	NCT01571219	Mar 2012 → Jul 2013	rheumatoid arthritis	Celltrion	Completed	No outcome recorded
Phase 3	NCT01585155	Feb 2012 → Sep 2014	ulcerative colitis	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 3	NCT01532570	Jan 2012 → May 2014	Behcet disease	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 3	NCT01190839	Nov 2010 → Dec 2014	Crohn disease	Janssen Biotech, Inc.	Terminated	No outcome recorded
Phase 3	NCT00984568	Nov 2009 → Mar 2012	ulcerative colitis	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 3	NCT00833053	Oct 2009 → Apr 2011	psoriasis	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 3	NCT00844805	Sep 2009 → Apr 2011	ankylosing spondylitis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00760435	Mar 2009 → Oct 2012	Kawasaki disease	University of California, San Diego	Completed	No outcome recorded
Phase 3	NCT01177800	Feb 2009 → Feb 2010	psoriasis	Xian-Janssen Pharmaceutical Ltd.	Completed	No outcome recorded
Phase 3	NCT02779114	Jan 2009 → Dec 2017	rheumatoid arthritis	University of Erlangen-Nürnberg Medical School	Unknown	No outcome recorded
Phase 3	NCT00805766	Dec 2008 → Nov 2009	Crohn disease	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 3	NCT00686686	Dec 2007 → Feb 2009	psoriasis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00537316	Jul 2007 → Feb 2010	ulcerative colitis	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 3	NCT00527072	Jul 2007 → May 2009	psoriasis	Centocor Ortho Biotech Services, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00521924	Jun 2007 → Apr 2008	rheumatoid arthritis	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 3	NCT01423591	Jun 2007 → Sep 2010	polymyalgia rheumatica	Hospital Universitario Marqués de Valdecilla	Unknown	No outcome recorded
Phase 3	NCT00385086	Feb 2007 → Oct 2012	lumbar stenosis, familial	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT00336492	Sep 2006 → May 2009	ulcerative colitis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00732875	Aug 2006 → May 2008	rheumatoid arthritis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00687401	Jun 2006 → May 2009	psoriasis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00358670	May 2006 → Jan 2009	psoriasis	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 3	NCT00367237	May 2006 → Mar 2008	psoriatic arthritis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00394589	Mar 2006 → Oct 2008	rheumatoid arthritis	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 3	NCT00571337	Dec 2005 → Jul 2010	Crohn disease	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Completed	No outcome recorded
Phase 3	NCT00251641	Sep 2005 → Jun 2008	psoriasis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00691028	Sep 2005 → May 2007	rheumatoid arthritis	Tanabe Pharma Corporation	Completed	No outcome recorded
Phase 3	NCT00254982	Aug 2005 → Sep 2006	psoriasis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00237484	Jul 2005 → Jun 2011	chronic hepatitis C virus infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00202852	Jun 2005 → Mar 2006	rheumatoid arthritis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00202865	May 2005 → May 2007	ankylosing spondylitis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00094458	Mar 2005 → Apr 2008	Crohn disease	Centocor Ortho Biotech Services, L.L.C.	Completed	No outcome recorded
Phase 3	NCT00796250	Nov 2003 → Jan 2005	Crohn disease	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 3	NCT00073437	Oct 2003 → Feb 2005	sarcoidosis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00317538	Jun 2003 → Nov 2004	rheumatoid arthritis	Centocor Ortho Biotech Services, L.L.C.	Completed	No outcome recorded
Phase 3	NCT01015547	May 2003 → Nov 2007	polyarticular juvenile idiopathic arthritis	Helsinki University Central Hospital	Completed	No outcome recorded
Phase 3	NCT00051623	May 2003 → Jun 2004	psoriatic arthritis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00439283	Apr 2003 → Dec 2004	ankylosing spondylitis	Association de Recherche Clinique en Rhumatologie	Completed	No outcome recorded
Phase 3	NCT00207675	Feb 2003 → Aug 2007	Crohn disease	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00106847	Jan 2003 → Jul 2005	parapsoriasis, psoriasis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00056264	Dec 2002 → Dec 2004	chronic obstructive pulmonary disease	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00040885	Oct 2002 → Feb 2006	eating disorder, lung cancer	Alliance for Clinical Trials in Oncology	Completed	No outcome recorded
Phase 3	NCT00207701	Sep 2002 → Feb 2005	ankylosing spondylitis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00096655	May 2002 → Aug 2007	ulcerative colitis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00036439	Feb 2002 → Jan 2007	ulcerative colitis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00036374	Oct 2001 → Dec 2006	juvenile idiopathic arthritis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00207662	Jul 2000 → Nov 2005	Crohn disease	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00207766	Jun 2000 → Aug 2006	Crohn disease	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00269867	Mar 1997 → Mar 2000	rheumatoid arthritis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00004941	Jul 1996	Crohn disease	FDA Office of Orphan Products Development	Completed	No outcome recorded
Phase 3	NCT00269841	May 1996 → Feb 1998	Crohn disease	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00106834	? → Oct 2004	psoriasis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00036387	? → Nov 2003	rheumatoid arthritis	Centocor, Inc.	Completed	No outcome recorded
Phase 3	NCT00236028	? → Apr 2003	rheumatoid arthritis	Centocor, Inc.	Completed	No outcome recorded

Phase 469 trials
Phase 4	NCT07352566	Aug 2026 → Jun 2030 expected	atopic eczema, psoriasis	University of California, San Francisco	Not yet recruiting	No outcome recorded
Phase 4	NCT07683975	Jul 2026 → Jan 2029 expected	acute kidney injury, acute tubulointerstitial nephritis	Massachusetts General Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT07576452	Jun 2026 → Jun 2030 expected	ulcerative colitis	University Hospital, Clermont-Ferrand	Not yet recruiting	No outcome recorded
Phase 4	NCT07510191	Mar 2026 → Dec 2028 expected	Crohn disease	Sixth Affiliated Hospital, Sun Yat-sen University	Recruiting	No outcome recorded
Phase 4	NCT05823532	Apr 2024 → Mar 2028 expected	schizophrenia	Emory University	Recruiting	No outcome recorded
Phase 4	NCT06051253	Nov 2023 → Jun 2026 overdue	perianal Crohn disease	Asan Medical Center	Recruiting	No outcome recorded
Phase 4	NCT05906576	Sep 2023 → Nov 2026 expected	Crohn disease	Taizhou Mabtech Pharmaceutical Co.,Ltd	Recruiting	No outcome recorded
Phase 4	NCT05552287	Aug 2023 → Aug 2025 overdue	Crohn disease	Erasmus Medical Center	Recruiting	No outcome recorded
Phase 4	NCT05781152	Jun 2023 → Jul 2028 expected	Crohn disease	Connecticut Children's Medical Center	Recruiting	No outcome recorded
Phase 4	NCT05813860	Apr 2023 → May 2026 overdue	Crohn disease	Sixth Affiliated Hospital, Sun Yat-sen University	Not yet recruiting	No outcome recorded
Phase 4	NCT05169593	Sep 2022 → Oct 2027 expected	Crohn disease	Universitaire Ziekenhuizen KU Leuven	Recruiting	No outcome recorded
Phase 4	NCT06043752	Mar 2022 → Jul 2023	psoriasis	Ghurki Trust and Teaching Hospital	Completed	No outcome recorded
Phase 4	NCT05280405	Mar 2022 → Jan 2024	inflammatory bowel disease	IRCCS Burlo Garofolo	Unknown	No outcome recorded
Phase 4	NCT05220280	Feb 2022 → Dec 2024	COVID-19	Clinical Urology and Epidemiology Working Group	Unknown	No outcome recorded
Phase 4	NCT05164198	Jan 2022 → Oct 2024	ankylosing spondylitis	Hanyang University Seoul Hospital	Unknown	No outcome recorded
Phase 4	NCT05273242	Dec 2021 → Dec 2022	COVID-19	Nepal Health Research Council	Unknown	No outcome recorded
Phase 4	NCT05115903	Dec 2021 → Jul 2024	spondyloarthropathy	University Health Network, Toronto	Unknown	No outcome recorded
Phase 4	NCT04999228	Nov 2021 → Jun 2025 overdue	ulcerative colitis	Children's Hospital of Fudan University	Recruiting	No outcome recorded
Phase 4	NCT04835506	Nov 2021 → Sep 2026 expected	Crohn disease, ulcerative colitis	Beth Israel Deaconess Medical Center	Active not recruiting	No outcome recorded
Phase 4	NCT04646187	Mar 2021 → Mar 2026 overdue	Crohn disease, ulcerative colitis	University Medical Center Groningen	Enrolling by invitation	No outcome recorded
Phase 4	NCT05340764	Aug 2020 → May 2023	inflammatory bowel disease	Washington University School of Medicine	Completed	No outcome recorded
Phase 4	NCT03937609	Sep 2019 → Dec 2024	ulcerative colitis	Academic Medical Center - University of Amsterdam	Terminated	No outcome recorded
Phase 4	NCT03679546	Jan 2019 → Dec 2024	ulcerative colitis	Rennes University Hospital	Completed	No outcome recorded
Phase 4	NCT04775732	Jun 2018 → Aug 2019	Crohn disease, ulcerative colitis	Imelda GI Clinical Research Center	Completed	No outcome recorded
Phase 4	NCT03004443	May 2017 → Nov 2019	depressive disorder	Emory University	Terminated	No outcome recorded
Phase 4	NCT04150770	Jan 2017 → Jan 2020	uveitis	Xiaomin Zhang	Unknown	No outcome recorded
Phase 4	NCT03006393	Aug 2016 → Sep 2020	depressive disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT02770794	Apr 2016 → Aug 2020	rheumatoid arthritis	Chiba University	Completed	No outcome recorded
Phase 4	NCT02566889	Apr 2016 → Jul 2019	inflammatory bowel disease	Janssen Scientific Affairs, LLC	Terminated	No outcome recorded
Phase 4	NCT02714634	Mar 2016 → Mar 2029 expected	rheumatoid arthritis	University Hospital, Strasbourg, France	Recruiting	No outcome recorded
Phase 4	NCT02878161	Jan 2016 → Dec 2019	rheumatoid arthritis	Fen Li	Unknown	No outcome recorded
Phase 4	NCT02177071	Oct 2015 → Jun 2021	Crohn disease	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Completed	No outcome recorded
Phase 4	NCT02453776	May 2015 → Dec 2018	inflammatory bowel disease	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
Phase 4	NCT02517684	Apr 2015 → Dec 2019	Crohn disease	Erasmus Medical Center	Completed	No outcome recorded
Phase 4	NCT02148640	Oct 2014 → Jun 2016	Crohn disease, psoriasis, psoriatic arthritis, spondyloarthropathy +1	Diakonhjemmet Hospital	Completed	No outcome recorded
Phase 4	NCT02132234	Jun 2013 → Jul 2014	ankylosing spondylitis, hypertensive disorder, psoriatic arthritis	Jagiellonian University	Unknown	No outcome recorded
Phase 4	NCT01880307	Jan 2013 → Dec 2014	Crohn disease	Erasmus Medical Center	Terminated	No outcome recorded
Phase 4	NCT01752790	Dec 2012 → Jan 2014	Crohn disease	University of Roma La Sapienza	Withdrawn	No outcome recorded
Phase 4	NCT01604629	Jul 2012 → Apr 2015	spondyloarthropathy	Spanish Clinical Pharmacology Society	Completed	No outcome recorded
Phase 4	NCT01181765	Jun 2012 → Jan 2013	small bowel Crohn disease	Janssen, LP	Completed	No outcome recorded
Phase 4	NCT01602302	Jun 2012 → Nov 2020	rheumatoid arthritis	Medical University of Graz	Terminated	No outcome recorded
Phase 4	NCT01638715	May 2012 → Aug 2018	rheumatoid arthritis	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT01548768	Oct 2011 → Sep 2019	rheumatoid arthritis	Columbia University	Completed	No outcome recorded
Phase 4	NCT01295151	Aug 2011 → Nov 2015	rheumatoid arthritis	Julia Brown	Completed	No outcome recorded
Phase 4	NCT01408810	Feb 2011 → Nov 2012	ulcerative colitis	Grupo de Estudo da Doença Inflamatória Intestinal	Completed	No outcome recorded
Phase 4	NCT01282528	Sep 2010 → ?	rheumatoid arthritis	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 4	NCT01148901	Jun → Dec 2010	ankylosing spondylitis	Merck Sharp & Dohme LLC	Withdrawn	No outcome recorded
Phase 4	NCT00463580	Dec 2008 → Jun 2011	depressive disorder	Emory University	Completed	No outcome recorded
Phase 4	NCT00752622	Nov 2008 → Jun 2010	Crohn disease	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 4	NCT00714493	Jul 2008 → Jan 2010	rheumatoid arthritis	Centocor Ortho Biotech Services, L.L.C.	Completed	No outcome recorded
Phase 4	NCT00726804	Mar 2008 → May 2012	spondyloarthropathy	Glostrup University Hospital, Copenhagen	Terminated	No outcome recorded
Phase 4	NCT01072058	Feb 2008 → Feb 2011	ankylosing spondylitis	University of Sao Paulo	Unknown	No outcome recorded
Phase 4	NCT00686894	Jan → Nov 2008	ankylosing spondylitis	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 4	NCT00936143	Jan 2008 → Sep 2009	spondylitis	Gu Jieruo	Completed	No outcome recorded
Phase 4	NCT00686595	Oct 2007 → Oct 2009	psoriasis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00507403	Oct 2007 → Oct 2009	ankylosing spondylitis	University Hospital, Tours	Completed	No outcome recorded
Phase 4	NCT01144143	Jul 2007 → Dec 2010	osteoarthritis, knee	Herbert Lindsley, MD	Completed	No outcome recorded
Phase 4	NCT00896168	Jun 2007 → Apr 2008	rheumatoid arthritis	Xian-Janssen Pharmaceutical Ltd.	Completed	No outcome recorded
Phase 4	NCT00462072	Mar 2007 → Jun 2010	Crohn disease, psoriasis, psoriatic arthritis	University of Rochester	Completed	No outcome recorded
Phase 4	NCT01308255	Sep 2006 → Feb 2011	rheumatoid arthritis	University of Leeds	Completed	No outcome recorded
Phase 4	NCT00574470	Jan 2006 → Nov 2007	graft versus host disease	University of Iowa	Completed	No outcome recorded
Phase 4	NCT00216177	Sep 2005 → Jan 2009	rheumatoid arthritis	Hvidovre University Hospital	Unknown	No outcome recorded
Phase 4	NCT00778869	Aug 2005	ankylosing spondylitis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00779935	Oct 2004 → Oct 2005	ankylosing spondylitis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00779012	Oct 2004 → Jun 2007	ankylosing spondylitis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00133315	Sep 2004 → Apr 2007	ankylosing spondylitis, psoriatic arthritis	Hvidovre University Hospital	Completed	No outcome recorded
Phase 4	NCT00794898	Jul 2003 → Apr 2004	rheumatoid arthritis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00246064	Dec 2001 → Nov 2003	rheumatoid arthritis	Centocor Ortho Biotech Services, L.L.C.	Completed	No outcome recorded
Phase 4	NCT00554710	May 2001 → Jan 2004	Crohn disease	Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW	Completed	No outcome recorded

Phase not applicable18 trials
—	NCT05584228	Oct 2026 → Apr 2030 expected	Crohn disease	Nantes University Hospital	Not yet recruiting	No outcome recorded
—	NCT07424040	Mar 2026 → Nov 2028 expected	Crohn disease	The Children's Hospital of Zhejiang University School of Medicine	Not yet recruiting	No outcome recorded
—	NCT07176754	Oct 2025 → Jul 2028 expected	cardiac arrest, post-cardiac arrest syndrome	Peking University Third Hospital	Active not recruiting	No outcome recorded
—	NCT07491913	Jun 2025 → Dec 2027 expected	Takayasu arteritis	Marmara University	Recruiting	No outcome recorded
—	NCT06758024	Jan 2025 → Jan 2026 overdue	Crohn disease, ulcerative colitis	Pontificia Universidad Catolica de Chile	Recruiting	No outcome recorded
—	NCT06064864	Oct 2023 → Dec 2026 expected	Crohn disease	Asan Medical Center	Recruiting	No outcome recorded
—	NCT04378621	Oct 2020 → Sep 2025	depressive disorder, rheumatoid arthritis, subjective cognitive decline	Vastra Gotaland Region	Unknown	No outcome recorded
—	NCT03209232	Apr 2018 → Sep 2021	ulcerative colitis	Schneider Children's Medical Center, Israel	Terminated	No outcome recorded
—	NCT03370601	Jan 2017 → Jan 2019	inflammatory bowel disease	University Hospital, Lille	Terminated	No outcome recorded
—	NCT02522169	Sep 2015 → Dec 2016	Crohn disease	Klinikum Westbrandenburg GmbH	Unknown	No outcome recorded
—	NCT01915537	Aug 2013 → Dec 2015	rheumatoid arthritis	Zhang, Xiao, M.D.	Unknown	No outcome recorded
—	NCT01438151	Dec 2011 → Dec 2013	Crohn disease	Shradha Agarwal	Terminated	No outcome recorded
—	NCT01361542	Feb → Dec 2011	ankylosing spondylitis	All India Institute of Medical Sciences	Completed	No outcome recorded
—	NCT01266785	Dec 2010 → Jul 2012	Crohn disease	Oregon Health and Science University	Withdrawn	No outcome recorded
—	NCT00791557	Oct 2008 → Dec 2009	Crohn disease, pyoderma gangrenosum, ulcerative colitis	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
—	NCT01245361	Nov 2007 → Dec 2011	arthritic joint disease	Patrick Durez	Completed	No outcome recorded
—	NCT00237419	Dec 2005 → Nov 2010	ankylosing spondylitis	Rheumazentrum Ruhrgebiet	Unknown	No outcome recorded
—	NCT00273390	Aug 2001 → Dec 2006	uveitis	Oregon Health and Science University	Completed	No outcome recorded

Also used as a comparator or background therapy in 111 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 18 trials
Phase 1	NCT05912712 Background	Jul 2023 → Jun 2025	solitary rectal ulcer syndrome, ulcerative colitis	Xijing Hospital of Digestive Diseases	Unknown	No outcome recorded
Phase 1	NCT03819296 Background	Feb 2021 → Oct 2026 expected	colitis, cutaneous melanoma, lung carcinoma in situ, malignant urinary system neoplasm +1	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 1	NCT02883452 Comparator	Sep 2016 → Feb 2019	Crohn disease, ulcerative colitis	Celltrion	Completed	No outcome recorded
Phase 1	NCT01931189 Comparator	Aug 2013 → Jan 2014	—	Nichi-Iko Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01844804 Comparator	May → Nov 2013	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT01571206 Comparator	Mar 2012 → May 2013	ankylosing spondylitis	Celltrion	Completed	No outcome recorded
Phase 1	NCT01567358 Comparator	Feb → Dec 2012	rheumatoid arthritis	Nichi-Iko Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT01220518 Comparator	Oct 2010 → Nov 2011	ankylosing spondylitis	Celltrion	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT04407247 Comparator	Jul 2020 → Dec 2027 expected	colitis, malignant urinary system neoplasm, melanoma, non-small cell lung carcinoma	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 1/2	NCT04082910 Background	Sep 2019 → Dec 2022	cancer, hematopoietic and lymphoid cell neoplasm	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 214 trials
Phase 2	NCT07619898 Comparator	Jul 2026 → Dec 2028 expected	colitis, hepatitis, melanoma	Therakos	Not yet recruiting	No outcome recorded
Phase 2	NCT06646016 Comparator	Dec 2025 → Feb 2026	colitis	Therakos	Withdrawn	No outcome recorded
Phase 2	NCT06075706 Comparator	Nov 2023 → Feb 2026 overdue	acute graft versus host disease	medac GmbH	Active not recruiting	No outcome recorded
Phase 2	NCT04118556 Comparator	Dec 2021 → Apr 2026	acute graft versus host disease	Mats Remberger	Terminated	No outcome recorded
Phase 2	NCT04891991 Comparator	Nov 2021 → Nov 2023	proliferative vitreoretinopathy, rhegmatogenous retinal detachment	Cairo University	Completed	No outcome recorded
Phase 2	NCT04797325 Background	Aug 2021 → Apr 2025	—	University of Copenhagen	Unknown	No outcome recorded
Phase 2	NCT05168475 Comparator	Jul 2021 → Nov 2023	Cogan syndrome, Cryoglobulinemic vasculitis, Takayasu arteritis, cutaneous polyarteritis nodosa +4	Cambridge University Hospitals NHS Foundation Trust	Terminated	No outcome recorded
Phase 2	NCT03684278 Comparator	May 2019 → Dec 2026 expected	acute pancreatitis	University of Liverpool	Recruiting	No outcome recorded
Phase 2	NCT02694770 Comparator	Jul 2016 → Sep 2017	acute graft versus host disease	AbGenomics B.V Taiwan Branch	Withdrawn	No outcome recorded
Phase 2	NCT02770430 Comparator	Sep 2015 → Sep 2017	acute graft versus host disease	Hospital de Clinicas de Porto Alegre	Unknown	No outcome recorded
Phase 2	NCT02251041 Comparator	Sep 2014 → Feb 2019	—	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 2	NCT00808210 Comparator	Mar 2009 → Nov 2012	rheumatoid arthritis	Genentech, Inc.	Terminated	No outcome recorded
Phase 2	NCT00304954 Comparator	Feb 2006 → Jan 2010	age-related macular degeneration, choroidal neovascularization	National Eye Institute (NEI)	Completed	No outcome recorded
Phase 2	NCT00207714 Background	Nov 2003 → Feb 2005	rheumatoid arthritis	Centocor, Inc.	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT04898231 Comparator	Dec 2020 → Dec 2023	COVID-19–associated multisystem inflammatory syndrome in children	University of California, San Diego	Completed	No outcome recorded
Phase 2/3	NCT02532738 Background	Jan 2016 → Nov 2018	Crohn disease	Sixth Affiliated Hospital, Sun Yat-sen University	Unknown	No outcome recorded
Phase 329 trials
Phase 3	NCT04593940 Comparator	Oct 2020 → Jan 2022	COVID-19	Daniel Benjamin	Completed	No outcome recorded
Phase 3	NCT04505410 Comparator	Sep 2020 → Dec 2023	ulcerative colitis	University of Miami	Completed	No outcome recorded
Phase 3	NCT03707535 Comparator	Nov 2018 → Mar 2020	rheumatoid arthritis	Celltrion	Completed	No outcome recorded
Phase 3	NCT03478111 Comparator	Mar 2018 → Jun 2019	rheumatoid arthritis	Shanghai Biomabs Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03221166 Comparator	Feb 2018 → Jul 2020	Crohn disease	IRCCS Burlo Garofolo	Terminated	No outcome recorded
Phase 3	NCT04178850 Comparator	Oct 2017 → Dec 2020	rheumatoid arthritis	Genor Biopharma Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT03112603 Comparator	Jun 2017 → May 2020	chronic graft versus host disease	Incyte Corporation	Completed	No outcome recorded
Phase 3	NCT02913261 Comparator	Mar 2017 → Jun 2019	acute graft versus host disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT03065244 Comparator	Feb 2017 → Aug 2020	Kawasaki disease	University of California, San Diego	Completed	No outcome recorded
Phase 3	NCT02937701 Comparator	Oct 2016 → Apr 2018	rheumatoid arthritis	Amgen	Completed	No outcome recorded
Phase 3	NCT03147248 Comparator	Sep 2016 → May 2018	rheumatoid arthritis	Celltrion	Completed	No outcome recorded
Phase 3	NCT02683564 Comparator	Feb 2016 → Jul 2017	rheumatoid arthritis	Epirus Biopharmaceuticals (Switzerland) GmbH	Unknown	No outcome recorded
Phase 3	NCT02762838 Comparator	Jan 2016 → Jul 2018	rheumatoid arthritis	Biocad	Completed	No outcome recorded
Phase 3	NCT02762812 Comparator	Jan 2016 → May 2017	ankylosing spondylitis	Biocad	Completed	No outcome recorded
Phase 3	NCT02136069 Comparator	Dec 2014 → Jun 2020	ulcerative colitis	Hoffmann-La Roche	Completed	No outcome recorded
Phase 3	NCT02332356 Comparator	Sep 2014 → Mar 2024	Crohn disease	Tokyo Medical and Dental University	Unknown	No outcome recorded
Phase 3	NCT02222493 Comparator	Aug 2014 → Jun 2016	rheumatoid arthritis	Pfizer	Completed	No outcome recorded
Phase 3	NCT06441526 Comparator	Sep 2013 → Dec 2019	Crohn disease, anal fistula	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
Phase 3	NCT01936181 Comparator	Aug 2013 → Sep 2014	rheumatoid arthritis	Samsung Bioepis Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01927263 Comparator	Jul 2013 → Mar 2015	rheumatoid arthritis	Nichi-Iko Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01724268 Comparator	May 2012 → May 2014	rheumatoid arthritis	Hamad Medical Corporation	Unknown	No outcome recorded
Phase 3	NCT01217086 Comparator	Oct 2010 → Nov 2011	rheumatoid arthritis	Celltrion	Completed	No outcome recorded
Phase 3	NCT01661257 Background	Oct 2009 → Jun 2011	Crohn disease	Samsung Medical Center	Completed	No outcome recorded
Phase 3	NCT01559142 Comparator	Nov 2008 → Apr 2012	Crohn disease	Children's Memorial Health Institute, Poland	Unknown	No outcome recorded
Phase 3	NCT03414502 Comparator	Dec 2007 → Mar 2028 expected	rheumatoid arthritis	University of Nebraska	Recruiting	No outcome recorded
Phase 3	NCT00505947 Comparator	Jul 2007 → Dec 2008	diabetic macular edema	University of Athens	Terminated	No outcome recorded
Phase 3	NCT00629772 Comparator	Mar 2007 → Feb 2009	psoriasis	Innovaderm Research Inc.	Completed	No outcome recorded
Phase 3	NCT00124982 Background	Apr 2005 → Aug 2009	rheumatoid arthritis	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00095147 Comparator	Feb 2005 → Jul 2009	rheumatoid arthritis	Bristol-Myers Squibb	Completed	No outcome recorded

Phase 440 trials
Phase 4	NCT07550673 Comparator	Apr 2026 → Apr 2028 expected	ulcerative colitis	Xijing Hospital of Digestive Diseases	Recruiting	No outcome recorded
Phase 4	NCT07415473 Comparator	Apr 2026 → Mar 2029 expected	Crohn disease	Chinese Medical Association	Not yet recruiting	No outcome recorded
Phase 4	NCT07417696 Comparator	Apr 2026 → Mar 2029 expected	Crohn disease	Chinese Medical Association	Not yet recruiting	No outcome recorded
Phase 4	NCT06113913 Comparator	Apr 2024 → May 2026 overdue	Crohn disease, ulcerative colitis	Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW	Recruiting	No outcome recorded
Phase 4	NCT05928039 Comparator	Oct 2023 → Jul 2027 expected	Crohn disease	University of Calgary	Recruiting	No outcome recorded
Phase 4	NCT05043870 Comparator	Oct 2022 → Oct 2026 expected	Crohn disease	Children's Hospital of Fudan University	Recruiting	No outcome recorded
Phase 4	NCT04530877 Comparator	Oct 2022 → Sep 2024	Crohn disease	Children's Hospital of Fudan University	Withdrawn	No outcome recorded
Phase 4	NCT05313620 Comparator	Apr 2022 → Dec 2025 overdue	ulcerative colitis, venous thromboembolism	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Recruiting	No outcome recorded
Phase 4	NCT04982172 Comparator	Feb → Nov 2022	inflammatory bowel disease	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 4	NCT05205603 Background	Jan 2022 → Jan 2024	ulcerative colitis	Sixth Affiliated Hospital, Sun Yat-sen University	Completed	No outcome recorded
Phase 4	NCT03885713 Comparator	Sep 2019 → Dec 2024	Crohn disease, ulcerative colitis	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Completed	No outcome recorded
Phase 4	NCT03445845 Comparator	Dec 2018 → Sep 2024	spondyloarthropathy	University Hospital of Saint-Etienne	Completed	No outcome recorded
Phase 4	NCT03580876 Background	Jul 2018 → Jun 2019	—	Védrines, Philippe, M.D.	Unknown	No outcome recorded
Phase 4	NCT03100253 Comparator	Mar 2018 → Dec 2021	rheumatoid arthritis	Mario Negri Institute for Pharmacological Research	Terminated	No outcome recorded
Phase 4	NCT03151525 Comparator	May 2017 → Oct 2019	ulcerative colitis	Istituto Clinico Humanitas	Unknown	No outcome recorded
Phase 4	NCT02994836 Comparator	Apr 2017 → Dec 2021	Crohn disease, ulcerative colitis	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	Completed	No outcome recorded
Phase 4	NCT02425852 Comparator	Dec 2016 → Jun 2022	ulcerative colitis	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Completed	No outcome recorded
Phase 4	NCT02770040 Comparator	Jul 2016 → Oct 2021	ulcerative colitis	Austin Health	Completed	No outcome recorded
Phase 4	NCT02452151 Comparator	Aug 2015 → Aug 2016	Crohn disease, ulcerative colitis	Onze Lieve Vrouwe Gasthuis	Unknown	No outcome recorded
Phase 4	NCT02242474 Comparator	Jul 2015 → Oct 2019	rheumatoid arthritis	CHU de Quebec-Universite Laval	Unknown	No outcome recorded
Phase 4	NCT02743390 Comparator	Mar 2015 → Jul 2017	hypertensive disorder	University of Campinas, Brazil	Completed	No outcome recorded
Phase 4	NCT02353780 Comparator	Mar 2015 → Dec 2017	rheumatoid arthritis	Dr. Larry W. Moreland	Terminated	No outcome recorded
Phase 4	NCT02236481 Comparator	Jul 2013 → Dec 2017	rheumatoid arthritis, type 2 diabetes mellitus	Prof. Roberto Giacomelli	Terminated	No outcome recorded
Phase 4	NCT01804166 Background	Mar 2013 → Feb 2020	hepatosplenic T-cell lymphoma	Janssen Scientific Affairs, LLC	Completed	No outcome recorded
Phase 4	NCT01817426 Comparator	Jan 2013 → May 2020	Crohn disease	Copenhagen University Hospital at Herlev	Completed	No outcome recorded
Phase 4	NCT01793519 Comparator	Jan 2013 → Jun 2024	rheumatoid arthritis	Georgetown University	Unknown	No outcome recorded
Phase 4	NCT01442025 Comparator	Jun 2012 → Jul 2015	Crohn disease	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Completed	No outcome recorded
Phase 4	NCT01346826 Comparator	May 2011 → Oct 2015	Crohn disease, ulcerative colitis	Asan Medical Center	Completed	No outcome recorded
Phase 4	NCT01237262 Comparator	Nov 2010	psoriasis	University of Padova	Unknown	No outcome recorded
Phase 4	NCT01000441 Comparator	Dec 2009 → Aug 2013	rheumatoid arthritis	University Hospital, Strasbourg, France	Completed	No outcome recorded
Phase 4	NCT00589628 Comparator	Sep 2007 → Dec 2010	uveitis	Egla C. Rabinovich	Completed	No outcome recorded
Phase 4	NCT00542152 Comparator	Jun 2007	ulcerative colitis	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	Completed	No outcome recorded
Phase 4	NCT00432406 Comparator	May 2006 → Mar 2009	psoriatic arthritis	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT00636142 Comparator	Sep 2005 → Jun 2007	metabolic syndrome X, obesity disorder	Medical University of Graz	Completed	No outcome recorded
Phase 4	NCT00132691 Comparator	Sep 2005 → Dec 2010	uveitis	JHSPH Center for Clinical Trials	Completed	No outcome recorded
Phase 4	NCT00432432 Comparator	Feb 2005 → Aug 2006	ankylosing spondylitis	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT00688636 Comparator	Jan 2005 → Aug 2008	Crohn disease	University of Pittsburgh	Completed	No outcome recorded
Phase 4	NCT00396747 Comparator	Jun 2003 → Sep 2005	rheumatoid arthritis	Catholic University of Louvain	Completed	No outcome recorded
Phase 4	NCT00908089 Comparator	Mar 2003 → May 2007	rheumatoid arthritis	University of Helsinki	Unknown	No outcome recorded
Phase 4	NCT00764725 Comparator	Dec 2002 → Apr 2007	rheumatoid arthritis	Karolinska Institutet	Completed	No outcome recorded

Phase not applicable16 trials
—	NCT07529236 Background	Apr 2026 → Oct 2027 expected	inflammatory bowel disease	Centre Hospitalier Universitaire de Nice	Recruiting	No outcome recorded
—	NCT07149441 Background	Aug 2025 → Sep 2028 expected	inflammatory bowel disease	Shanghai 10th People's Hospital	Active not recruiting	No outcome recorded
—	NCT06896305 Background	May 2025 → Apr 2027 expected	Crohn disease, ulcerative colitis	IRCCS Ospedale San Raffaele	Recruiting	No outcome recorded
—	NCT05931458 Comparator	Jul 2023 → Jul 2024 overdue	ulcerative colitis	Federico II University	Not yet recruiting	No outcome recorded
—	NCT05291039 Comparator	Jan 2022 → Mar 2023	inflammatory bowel disease	Rehab Werida	Completed	No outcome recorded
—	NCT04761952 Background	Feb 2021 → Dec 2022	Crohn disease, cephalin lipidosis	Sixth Affiliated Hospital, Sun Yat-sen University	Unknown	No outcome recorded
—	NCT03393247 Comparator	Jun 2017 → Jul 2018	Crohn disease	Sixth Affiliated Hospital, Sun Yat-sen University	Unknown	No outcome recorded
—	NCT02998827 Comparator	Nov 2016 → Nov 2017	Crohn disease	Sixth Affiliated Hospital, Sun Yat-sen University	Unknown	No outcome recorded
—	NCT02694588 Comparator	Jun 2014 → Oct 2018	inflammatory bowel disease	University Hospital Schleswig-Holstein	Completed	No outcome recorded
—	NCT01657513 Background	Jun 2012 → Jul 2013	psoriasis	University Hospital, Gentofte, Copenhagen	Unknown	No outcome recorded
—	NCT01610947 Comparator	May 2012 → Oct 2018	spondyloarthropathy	University Hospital, Montpellier	Completed	No outcome recorded
—	NCT00901550 Comparator	Nov 2008 → Oct 2011	rheumatoid arthritis	Chinese University of Hong Kong	Completed	No outcome recorded
—	NCT00948610 Comparator	Nov 2008 → Apr 2011	rheumatoid arthritis	University of California, Los Angeles	Completed	No outcome recorded
—	NCT02711202 Comparator	Jan 2007 → Mar 2009	—	Institute for Clinical and Experimental Medicine	Completed	No outcome recorded
—	NCT00307593 Comparator	May 2004 → Jun 2007	eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
—	NCT00252369 Background	—	perianal Crohn disease	Sheba Medical Center	Terminated	No outcome recorded

Press releases naming this drug 14 releases

Date	Issuer	Release
2019-12-06	Amgen	FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab) amgen.com ↗
2018-12-17	Amgen	Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration amgen.com ↗
2018-06-27	Amgen	Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab amgen.com ↗
2018-06-15	Novartis Pharmaceuticals	Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis novartis.com ↗
2018-05-24	Novartis Pharmaceuticals	Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases novartis.com ↗
2018-03-23	Novartis Pharmaceuticals	Sandoz receives positive CHMP opinion for proposed biosimilar infliximab novartis.com ↗
2017-10-29	Pfizer	One Year Maintenance and Switching Data in Patients with Crohn’s Disease Support the Use of INFLECTRA®* (infliximab CT-P13) in IBD1 pfizer.com ↗
2017-05-31	Novartis Pharmaceuticals	Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency novartis.com ↗
2017-02-17	Pfizer	New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a pfizer.com ↗
2016-10-17	Pfizer	Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb) pfizer.com ↗
2016-09-16	Pfizer	Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab) pfizer.com ↗
2016-04-05	Pfizer	FDA Approves INFLECTRA™ (Biosimilar Infliximab), The First U.S. Biosimilar Monoclonal Antibody, For All Eligible Indications pfizer.com ↗
2016-02-12	Novartis Pharmaceuticals	Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA novartis.com ↗
2016-02-09	Pfizer	Pfizer Commends The FDA Advisory Committee’s Vote To Approve Proposed Biosimilar Infliximab, The First Biosimilar Monoclonal Antibody Reviewed, For All Eligible Indications pfizer.com ↗

Evidence & citations 34 cited values

Every value below carries the sentence it was read from. 367 sources stand behind the page.

Field	Value	Cited text
Known as	infliximab	“The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗ 323 “The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ “Infliximab: Induction with 5 mg/kg intravenous (IV) at day 0, and 5 mg/kg IV at week 2; maintenance with 5 mg/kg IV at week 6, week 10 or week 14 and every eight weeks...” NCT05169593 ↗ “To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing...” NCT05115903 ↗ “Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2...” NCT01752790 ↗ “In severe refractory sarcoidosis not responding to conventional immunosuppressive treatment, the third-line tumor necrosis factor (TNF)-alpha inhibitor infliximab is an alternative.” NCT05689879 ↗ “TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi)” NCT04378621 ↗ “The infliximab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis” PMID 30929895 ↗ Mar 2019 “Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.” NCT00726804 ↗ “A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).” PMID 29504427 ↗ Mar 2018 “The purpose of this study is to improve the investigators understanding of the relationship between Crohn's disease and blood levels of the drug infliximab (Remicade).” NCT01438151 ↗ “* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.” NCT05273242 ↗ “Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study” NCT01361542 ↗ “Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.” NCT01638715 ↗ “new advanced therapy: Tofacitinib and Upadacitinib (JAK inhibitors), Infliximab (anti-TNF), Ustekinumab or Risankizumab (IL-23 inhibitors).” NCT04505410 ↗ “This trial will examine the efficacy and safety of 5 mg/kg doses of infliximab in patients with inhaled corticosteroid-dependent asthma.” NCT00278083 ↗ “Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months” NCT00124982 ↗ “Seton placement, followed by anti-TNF medication (infliximab or adalimumab) in combination with a immunomodulator after ± 2 weeks.” NCT06441526 ↗ “Participants were randomised to anakinra or to a TNFi (i.e., adalimumab, certolizumab pegol, etanercept, infliximab, or golimumab)” PMID 31513665 ↗ Sep 2019 “Anti-TNF drugs (infliximab and adalimumab) are used early in high-risk patients or when standard treatments have failed.” NCT07529236 ↗ “If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.” NCT02770430 ↗ “such as Etanercept and infliximab, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis” NCT02694770 ↗ “extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), etanercept, infliximab or ruxolitinib (RUX)” NCT06075706 ↗ “CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects” NCT03446976 ↗ “Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day.” NCT03580876 ↗ “Three Formulations of Infliximab (SB2, EU Sourced Remicade® and US Sourced Remicade®) in Healthy Subjects” NCT01922336 ↗ “Infliximab (IFX) is a kind of one of the anti-tumor necrosis factor agents (anti-TNF)” NCT05813860 ↗ “Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.” NCT00948610 ↗ “infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks” NCT03445845 ↗ “infliximab if initial failure to the receptor fusion protein, etanercept.” NCT03100253 ↗ “infliximab (IFX) versus sulfasalazine (SSZ) plus hydroxychloroquine (HCQ)” PMID 32433827 ↗ Aug 2021 “Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis” NCT06043752 ↗ “All patients will receive one shot Infliximab mAb at day 2.” NCT04114188 ↗ “Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg” NCT01724268 ↗ “The Drug including 6MP, AZA, infliximab and thalidomide” NCT02532738 ↗ “Methotrexate or leflunomide + infliximab or” NCT02714634 ↗ “5 mg/kg infliximab infusion for 2 hours.” NCT01346826 ↗ “TNF)-α inhibition with infliximab (IFX)” PMID 26596627 ↗ Nov 2015 “Infliximab 3mg/kg standard regime” NCT01308255 ↗ “Infliximab: 3 mg/kg / 8 weeks” NCT01604629 ↗ “Remicade-US (infliximab)” NCT02990806 ↗ “Infliximab (Remicade®)” NCT02779114 ↗ “Remicade (infliximab)” NCT01936181 ↗ “infliximab” NCT00132691 ↗ “Infliximab” NCT04797325 ↗ “Infliximab” NCT02242474 ↗ “infliximab” NCT00132691 ↗ NCT00512278 ↗ NCT00984568 ↗ NCT00201799 ↗ NCT04898231 ↗ NCT00687362 ↗ NCT02694588 ↗ NCT00073437 ↗ NCT02132234 ↗ NCT00443222 ↗ NCT00779012 ↗ NCT03819296 ↗ NCT00753103 ↗ NCT01072058 ↗ NCT05164198 ↗ NCT00271570 ↗ NCT05947669 ↗ NCT00307593 ↗ NCT00514982 ↗ NCT01817426 ↗ NCT04761952 ↗ NCT07176754 ↗ NCT01485055 ↗ NCT03006393 ↗ NCT03112603 ↗ NCT03221166 ↗ NCT00687401 ↗ NCT02522169 ↗ NCT01217086 ↗ NCT01000441 ↗ NCT01661257 ↗ NCT04178850 ↗ NCT02222493 ↗ NCT05928039 ↗ NCT01256489 ↗ NCT01880307 ↗ NCT01313520 ↗ NCT07683975 ↗ NCT01148901 ↗ NCT03679546 ↗ NCT02770040 ↗ NCT03065244 ↗ NCT05906576 ↗ NCT03885713 ↗ NCT00033891 ↗ NCT04530877 ↗ NCT01220518 ↗ NCT00368264 ↗ NCT02425852 ↗ NCT00439283 ↗ NCT00505947 ↗ NCT01408810 ↗ NCT00133315 ↗ NCT05043870 ↗ NCT02148640 ↗ NCT01931189 ↗ NCT06614387 ↗ NCT07576452 ↗ NCT00076726 ↗ NCT00833053 ↗ NCT00051623 ↗ NCT02517684 ↗ NCT00396747 ↗ NCT03393247 ↗ NCT00094458 ↗ NCT07417696 ↗ NCT01177800 ↗ NCT02770794 ↗ NCT02566889 ↗ NCT06059989 ↗ NCT00959725 ↗ NCT01216631 ↗ NCT03945019 ↗ NCT02177071 ↗ NCT00794898 ↗ NCT07619898 ↗ NCT03684278 ↗ NCT00463580 ↗ NCT03088293 ↗ NCT03151525 ↗ NCT01144143 ↗ NCT02771457 ↗ NCT00537316 ↗ NCT01190839 ↗ NCT07671222 ↗ NCT05313620 ↗ NCT00688636 ↗ NCT00317538 ↗ NCT00589628 ↗ NCT02743390 ↗ NCT01266785 ↗ NCT04999228 ↗ NCT01282528 ↗ NCT00230529 ↗ NCT03004443 ↗ NCT00752622 ↗ NCT05660746 ↗ NCT00844805 ↗ NCT00246064 ↗ NCT01657513 ↗ NCT02126020 ↗ NCT00896168 ↗ NCT01602302 ↗ NCT00521924 ↗ NCT04535518 ↗ NCT04835506 ↗ NCT05823532 ↗ NCT06896305 ↗ NCT05340764 ↗ NCT00521963 ↗ NCT00686894 ↗ NCT03704363 ↗ NCT04205643 ↗ NCT03371095 ↗ NCT02452151 ↗ NCT01571219 ↗ NCT00507403 ↗ NCT00060502 ↗ NCT04305145 ↗ NCT02638701 ↗ NCT04982172 ↗ NCT02251041 ↗ NCT00732875 ↗ NCT06051253 ↗ NCT04779892 ↗ NCT00283712 ↗ NCT07138898 ↗ NCT02998827 ↗ NCT03937609 ↗ NCT00604864 ↗ NCT02363738 ↗ NCT05584228 ↗ NCT00796250 ↗ NCT00358670 ↗ NCT06758024 ↗ NCT03414502 ↗ NCT04330690 ↗ NCT01559142 ↗ NCT00252369 ↗ NCT00112749 ↗ NCT01793519 ↗ NCT00936143 ↗ NCT05931458 ↗ NCT07657312 ↗ NCT01571206 ↗ NCT02453776 ↗ NCT00095147 ↗ NCT06453317 ↗ NCT07491913 ↗ NCT00527072 ↗ NCT03293784 ↗ NCT07352566 ↗ NCT05280405 ↗ NCT00591201 ↗ NCT00686595 ↗ NCT04438382 ↗ NCT07415473 ↗ NCT00629772 ↗ NCT06646016 ↗ NCT00542152 ↗ NCT06113913 ↗ NCT03704610 ↗ NCT01971814 ↗ NCT04646187 ↗ NCT01295151 ↗ NCT00106834 ↗ NCT04425538 ↗ NCT00554710 ↗ NCT00273390 ↗ NCT04775732 ↗ NCT04150770 ↗ NCT06941376 ↗ NCT02495077 ↗ NCT01927263 ↗ NCT00269841 ↗ NCT07297069 ↗ NCT00269854 ↗ NCT00207662 ↗ NCT03209232 ↗ NCT00269867 ↗ NCT00372723 ↗ NCT00571337 ↗ NCT01181765 ↗ NCT02620618 ↗ NCT00056264 ↗ NCT00106847 ↗ NCT00207675 ↗ NCT00574470 ↗ NCT00207701 ↗ NCT00207714 ↗ NCT01442025 ↗ NCT00036374 ↗ NCT01551290 ↗ NCT01245361 ↗ NCT00901550 ↗ NCT00908089 ↗ NCT00695682 ↗ NCT00074074 ↗ NCT07424040 ↗ NCT00336492 ↗ NCT01355614 ↗ NCT01237262 ↗ NCT00462072 ↗ NCT06136546 ↗ NCT00523354 ↗ NCT00367237 ↗ NCT00036387 ↗ NCT00808210 ↗ NCT00244192 ↗ NCT02359903 ↗ NCT00175266 ↗ NCT00236028 ↗ NCT05220280 ↗ NCT01567358 ↗ NCT04593940 ↗ NCT00237484 ↗ NCT02505568 ↗ NCT00036439 ↗ NCT00207766 ↗ NCT07510191 ↗ NCT07149441 ↗ NCT00823641 ↗ NCT00958906 ↗ NCT07550673 ↗ NCT02937701 ↗ NCT04082910 ↗ NCT02994836 ↗ NCT01423591 ↗ NCT04564001 ↗ NCT01015547 ↗ NCT00029042 ↗ NCT01804166 ↗ NCT05912712 ↗ NCT00795574 ↗ NCT00636142 ↗ NCT00432406 ↗ NCT04974099 ↗ NCT05205603 ↗ NCT05034536 ↗ NCT05168475 ↗ NCT04922827 ↗ NCT04407247 ↗ NCT02332356 ↗ NCT02763761 ↗ NCT00202865 ↗ NCT00237419 ↗ NCT00251641 ↗ NCT02136069 ↗ NCT00228839 ↗ NCT00394589 ↗ NCT01610947 ↗ NCT03596645 ↗ NCT00432432 ↗ NCT00304954 ↗ NCT05552287 ↗ NCT04610476 ↗ NCT01915537 ↗ NCT00075075 ↗ NCT00791557 ↗ NCT05291039 ↗ NCT03370601 ↗ NCT00202852 ↗ NCT00760435 ↗ NCT00254982 ↗ NCT00040885 ↗ NCT02298062 ↗ NCT05180994 ↗ NCT04891991 ↗ NCT00216177 ↗ NCT00096655 ↗ NCT00244179 ↗ NCT00325078 ↗ NCT02878161 ↗ NCT00714493 ↗ NCT02987686 ↗ NCT00111917 ↗ NCT00686686 ↗ NCT00006292 ↗
Known as	anbaite	“The TNF-α antagonist (infliximab) used by the experimenter was manufactured by Hisun Biopharmaceuticals Ltd. under the trade name "anbaite".” NCT07176754 ↗
Known as	Avsola	“Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗
Known as	cA2	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004941 ↗
Known as	CMAB008	“The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety” NCT04779892 ↗ 1 NCT03478111 ↗
Known as	CP-P13	“Infliximab(Remicade or CP-P13)” NCT01571219 ↗
Known as	CT-P13	“An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab...” NCT01571206 ↗ 12 “The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases.” PMID 32965617 ↗ Oct 2020 “CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile.” PMID 38788861 ↗ May 2024 “Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46.” NCT06051253 ↗ “CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®).” PMID 27038608 ↗ Apr 2016 “CT-P13 (Infliximab) is a monoclonal antibody currently being developed by CELLTRION, Inc.” NCT01571219 ↗ NCT06738719 ↗ NCT02883452 ↗ NCT02096861 ↗ NCT03147248 ↗ NCT03707535 ↗ NCT03446976 ↗ NCT06274294 ↗
Known as	CT-P13 SC	“Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled...” PMID 40243842 ↗ Jun 2025
Known as	EU-INF	“between SB2 and EU-sourced INF (EU-INF), between SB2 and US-sourced INF (US-INF), and between EU-INF and US-INF” PMID 26577771 ↗ Dec 2015
Known as	IFX	“This Phase IIIb, randomized, multi-national, multi-center, blinded study of Infliximab (IFX) in subjects aged 18 and older with active RA is being conducted to assess whether...” NCT00394589 ↗ 18 “One of the most effective therapies to treat patients with moderate to severe disease is the antitumor necrosis factor (TNF) agent infliximab (IFX) either as monotherapy or as...” NCT04835506 ↗ “The purpose of the study is to compare the effects of methotrexate (MTX) alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab (IFX) on...” NCT00396747 ↗ “Eligible patients were randomly assigned to receive infliximab (IFX) and azathioprine (AZA) with a 7-day steroid tapering scheme (IFX+AZA arm) or AZA and conventional...” PMID 39586616 ↗ Jan 2025 “Ulcerative colitis patients treated with Infliximab (IFX) in deep remission after at least 12 months of treatment will be randomized to continue IFX or to stop IFX and start...” NCT03151525 ↗ “Infliximab (IFX), a monoclonal chimeric antibody against tumour necrosis factor (TNF) α, is effective for induction and maintenance of remission in moderate to severe Crohn's disease.” PMID 25524543 ↗ Dec 2014 “The purpose of this study is to determine whether a top-down treatment approach, prescribing infliximab (IFX) and azathioprine (AZA) at diagnose, yields better outcome” NCT02517684 ↗ “In nine refractory CD patients (7 infliximab [IFX] non-responders, 2 FMT non-responders), IFX-FMT combination led to week-4 response in 6 patients” PMID 41870087 ↗ Mar 2026 “The tumor necrosis factor-alpha (TNF-alpha) inhibitor infliximab (IFX) has been proven effective for the treatment of ankylosing spondylitis (AS).” PMID 20231198 ↗ Mar 2010 “Infliximab (IFX) is a Food and Drug administration (FDA)-appoved monoclonal antibody medication targeting tumor necrosis factor (TNF)” NCT06758024 ↗ “Loss of response (LOR) to infliximab (IFX) remains a challenge in the management of inflammatory bowel diseases (IBD).” PMID 33290108 ↗ Dec 2020 “OBJECTIVE: We assessed the efficacy and safety of infliximab (IFX) for the treatment of moderate to severe HS.” PMID 20115947 ↗ Feb 2010 “Remicade (infliximab \[IFX\]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week” NCT00367237 ↗ “Infliximab (IFX) is a kind of one of the anti-tumor necrosis factor agents (anti-TNF)” NCT05813860 ↗ “Infliximab (IFX) is the first anti-TNF-α agent registered for pediatric CD.” NCT05552287 ↗ “infliximab (IFX) versus sulfasalazine (SSZ) plus hydroxychloroquine (HCQ)” PMID 32433827 ↗ Aug 2021 “infliximab (IFX) infusion; azathioprine (AZA) caps” NCT00094458 ↗ “TNF)-α inhibition with infliximab (IFX)” PMID 26596627 ↗ Nov 2015 “Infliximab (IFX)” NCT00537316 ↗
Known as	IIFX	“Infliximab with azathioprine (IIFX + AZA)” NCT01559142 ↗
Known as	INF	“Infliximab (INF) + MTX, DB” NCT00095147 ↗
Known as	Inflectra	“The investigational medicinal product is infliximab (Inflectra®, Hospira, or any of the other biosimilars of IFX according to the local availability in the participating...” NCT05552287 ↗ 5 “Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment.” NCT02452151 ↗ “Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered” NCT04982172 ↗ “switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra)” PMID 27130908 ↗ Apr 2016 “CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®).” PMID 27038608 ↗ Apr 2016 “Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗
Known as	Infliximab (generic)	“Infliximab (generic)” NCT01971814 ↗
Known as	Infliximab - REMICADE as brand name	“Infliximab - REMICADE as brand name” NCT01361542 ↗
Known as	Infliximab-dyyb	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06591273 ↗ 2 NCT06064864 ↗ NCT05663268 ↗
Known as	INX	“To compare the efficacy and safety of innovator infliximab (INX) and CT-P13, an INX biosimilar, in active rheumatoid arthritis patients with inadequate response to methotrexate...” PMID 23687260 ↗ May 2013
Known as	Remicade	“The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer...” NCT00060502 ↗ 60 “An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 in Patients With Ankylosing Spondylitis Who Were Treated With Infliximab...” NCT01571206 ↗ “A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an...” NCT01190839 ↗ “BACKGROUND: CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®) and is approved in Europe and elsewhere, mostly for the same...” PMID 26795209 ↗ Jan 2016 “A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab (REMICADE�) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response to...” NCT00527072 ↗ “Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.” PMID 22102701 ↗ Nov 2011 “Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce the pain of rheumatoid arthritis.” NCT00036387 ↗ “Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.” NCT00726804 ↗ “The purpose of this study is to improve the investigators understanding of the relationship between Crohn's disease and blood levels of the drug infliximab (Remicade).” NCT01438151 ↗ “The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.” NCT00336492 ↗ “The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Obstructive Pulmonary Disease (COPD).” NCT00056264 ↗ “Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.” NCT00106847 ↗ “Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.” NCT00051623 ↗ “The purpose of this study is to evaluate the safety and efficacy (effectiveness) of Infliximab (Remicade) in patients with Giant Cell Arteritis.” NCT00076726 ↗ “Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.” NCT01638715 ↗ “Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment.” NCT02452151 ↗ “The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.” NCT00230529 ↗ “The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Sarcoidosis.” NCT00073437 ↗ “The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.” NCT00036439 ↗ “The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.” NCT00096655 ↗ “Remicade (infliximab, chimeric mouse/human IgG1K monoclonal antibody directed against human TNF-alpha, Centocor, Malvern,PA)” NCT00273390 ↗ “A study of the safety and efficacy of infliximab (Remicade) in pediatric patients with moderate to severe Crohn's Disease” NCT00207675 ↗ “Control group: Infliximab (Remicade), administered intravenously at 5mg/kg every 8 weeks at weeks 0, 2, 6 and thereafter.” NCT07424040 ↗ “Two anti-TNFa agents are currently marketed for the treatment of RA; etanercept (Enbrel®) and infliximab (REMICADE®).” NCT00317538 ↗ “A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis” NCT00036374 ↗ “switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra)” PMID 27130908 ↗ Apr 2016 “Remicade (infliximab \[IFX\]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week” NCT00367237 ↗ “Three Formulations of Infliximab (SB2, EU Sourced Remicade® and US Sourced Remicade®) in Healthy Subjects” NCT01922336 ↗ “A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease” NCT00207766 ↗ “Infliximab (Remicade) is a genetically engineered antibody against a molecule in the body called TNF-α.” NCT00695682 ↗ “The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety” NCT04779892 ↗ “Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗ “The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.” NCT01548768 ↗ “A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.” NCT00207701 ↗ “TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )” NCT00368264 ↗ “Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis” NCT00033891 ↗ “a single dose infusion of 5mg/kg Remicade (Infliximab)” NCT00372723 ↗ “The name of the antibody is infliximab (Remicade)” NCT00207662 ↗ “Infliximab is the active drug in Remicade.” NCT00106834 ↗ “Infliximab (Remicade®)” NCT02779114 ↗ “REMICADE� (Infliximab)” NCT00094458 ↗ “Infliximab (Remicade®)” NCT00443222 ↗ “Infliximab (Remicade)” NCT00271570 ↗ “infliximab (Remicade)” NCT00236028 ↗ “infliximab (REMICADE)” NCT00714493 ↗ “infliximab (Remicade)” NCT00244192 ↗ NCT02990806 ↗ NCT02096861 ↗ NCT00779935 ↗ NCT02457585 ↗ NCT01844804 ↗ NCT03707535 ↗ NCT00778869 ↗ NCT02711202 ↗ NCT03478111 ↗ NCT01936181 ↗ NCT02353780 ↗ NCT02762812 ↗ NCT00948610 ↗ NCT02762838 ↗ NCT02683564 ↗
Known as	Remicade (Registered Trademark)	“This study will determine whether a stepwise increase of the drug infliximab (Remicade® (Registered Trademark)) controls juvenile rheumatoid arthritis more effectively than a...” NCT00029042 ↗ 1 “This small, preliminary study will examine whether multiple infusions of infliximab (Remicade® (Registered Trademark)) can control inflammation in patients with active scleritis.” NCT00075075 ↗
Known as	Remicade, SCH 215596	“Remicade, SCH 215596” NCT01148901 ↗
Known as	RemicadeTM	“Chimeric A2 (infliximab, RemicadeTM) IgG” NCT00604864 ↗
Known as	Remicaide	“Remicaide (infliximab)” NCT00372723 ↗
Known as	Remsima	“There are no clinical trials with Remsima® 120 mg given subcutaneously without IV loading doses of CT-P13 in patients with IBD.” NCT06274294 ↗ 4 “switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra)” PMID 27130908 ↗ Apr 2016 “CT-P13 (Remsima®, Inflectra®) is a biosimilar of the infliximab reference product (RP; Remicade®).” PMID 27038608 ↗ Apr 2016 “Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis” NCT06043752 ↗ “Infliximab-dyyb Biosimilar (Remsima)” NCT06591273 ↗
Known as	Remsima (infliximab-dyyb biosimilar)	“Remsima (infliximab-dyyb biosimilar)” NCT05663268 ↗
Known as	RemsimaTM	“Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46.” NCT06051253 ↗
Known as	Renflexis	“Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio” NCT05781152 ↗
Known as	SB2	“Three Formulations of Infliximab (SB2, EU Sourced Remicade® and US Sourced Remicade®) in Healthy Subjects” NCT01922336 ↗
Known as	TA-650	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01585155 ↗ 6 NCT00805766 ↗ NCT01680159 ↗ NCT01580670 ↗ NCT01596335 ↗ NCT00691028 ↗ NCT01532570 ↗
Known as	Top-down	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01752790 ↗
Known as	US-INF	“between SB2 and EU-sourced INF (EU-INF), between SB2 and US-sourced INF (US-INF), and between EU-INF and US-INF” PMID 26577771 ↗ Dec 2015
Action	Inhibit	“anti-TNF-alpha antibody” NCT00006292 ↗
Modality	Monoclonal antibody	“chimeric monoclonal antibody (cA2)” NCT00004941 ↗
Route	Intravenous	“The drug is given intravenously (IV, into a vein)” NCT00029042 ↗
Target	TNF	“a chimeric IgG(1) kappa monoclonal antibody against TNF” NCT00033891 ↗